Cellectar Biosciences is a clinical-stage company developing iopofosine I-131, a radioactive phospholipid drug conjugate, for relapsed or refractory Waldenstrom macroglobulinemia; it is not approved.
Cellectar's case rests on iopofosine I-131, a radioactive drug conjugate, for relapsed Waldenstrom macroglobulinemia, where 61.8% of 55 patients had a major response in a single-arm Phase 2b. It plans an NDA for accelerated approval in the first half of 2027, with the confirmatory Phase 3 expected to enroll first patients in early 2027. Cash of $34.0 million at June 30 lasts only into the second quarter of 2027, and Cellectar has disclosed substantial doubt about continuing as a going concern.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Cellectar files for accelerated approval
Does Cellectar submit a complete NDA on time, with the confirmatory trial underway as FDA expects?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cellectar plans to file iopofosine I-131 for U.S. accelerated approval in Waldenstrom macroglobulinemia in the first half of 2027 and to start its confirmatory Phase 3 in early 2027; cash of $34.0 million is expected to last into the second quarter of 2027
Iopofosine I-131's accelerated approval path in post-BTKi WM hinges on FDA accepting Phase 2b data as registrational and runway surviving confirmatory Phase 3 enrollment
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.